What are CAR T-Cells?
Chimeric antigen receptor T-cell (CAR T-cell) therapy is an immunotherapy that utilizes the patient's own T cells to fight cancer. In CAR T-cell therapy, a patient's T cells are collected and genetically modified to produce chimeric antigen receptors (CARs) on their surface. These CARs are designed to recognize and bind to a specific protein called an antigen that is found on the patient's cancer cells. Once reprogrammed with the CARs, the T cells are able to identify and destroy cancer cells that express the targeted antigen. This targeted approach allows the CAR T cells to selectively attack and eliminate cancer without harming normal cells.
How CAR T-Cells are Produced
Producing CAR T Cells is a multi-step process. First, T cells are collected from a patient through a process called leukopheresis. These T cells are then separated from other immune cells and expanded in number through culturing. Concurrently, a retrovirus or lentivirus is engineered to carry the genetic sequence that will program the T cells to express the CAR on their surface. The expanded T cells are then transduced with the retrovirus or lentivirus to stably insert the CAR gene into their DNA. After transduction, the genetically modified CAR T cells proliferate and expand further in culture. The CAR T cells are tested to ensure high CAR expression levels and potency against the targeted cancer cells. Lastly, the manufactured CAR T cells are infused back into the patient to treat their cancer.
Target Antigens for CAR T-Cell Therapies
Currently, the main antigens targeted by FDA-approved CAR T-cell therapies are CD19 and BCMA. CD19 is an antigen highly expressed in B cell leukemias and lymphomas. Novartis' Kymriah and Gilead's Yescarta target CD19 for the treatment of acute lymphoblastic leukemia and large B cell lymphoma, respectively. BCMA, also known as B-cell maturation antigen, is expressed on plasma cells and multiple myeloma cells. Treatment with anti-BCMA CAR T cells is being investigated for multiple myeloma. Other antigens under investigation include CD20, CD22, CD30, CD33, HER2, EGFRvIII, and GD2 which are expressed on various hematologic or solid tumor types. By targeting diverse tumor-associated antigens, CAR T-cell therapy may become applicable to many cancer indications.
Challenges with CAR T-Cell Therapies
While CAR T-cell therapy has revolutionized cancer treatment, it is also associated with safety concerns and challenges that need to be addressed. One of the most serious risks is cytokine release syndrome (CRS), which occurs when large numbers of CAR T cells are activated and release inflammatory cytokines all at once. CRS can cause high fever, low blood pressure, respiratory distress, and even life-threatening organ damage in severe cases. Another challenge is neurotoxicity which may arise due to CRS or directly from the CAR T cells infiltrating the brain. CRS and neurotoxicity are usually treatable but require close monitoring. Other concerns include limited persistence of CAR T cells in the body, restricted targeting to only antigen-expressing cancers, inability to cross the blood-brain barrier, and high treatment costs. Ongoing research aims to engineer safer and more effective CAR T cells to overcome these hurdles.
Potential of CAR T-Cell Therapies
Despite current drawbacks, CAR T-cell therapy holds promise as a promising new form of personalized cancer treatment. By surmounting major supply and production difficulties, its use could be expanded to reach more patients. Genetic modifications are under development to enable CAR T cells to proliferate and persist longer in the body. Using combination CARs that target two or more antigens may avert antigen escape variants. Additionally, CAR T cells are being engineered to traffic or cross biological barriers like the blood-brain barrier for hard-to-treat cancers. With further molecular refinements and larger clinical trials, CAR T-cell therapy could potentially be applied to various hematologic malignancies as well as solid tumor types in the future. Its ability to produce durable remissions even in heavily pretreated patients has transformed the outlook for many cancer patients. Continued research strives to maximize the benefits of this revolutionary technology while minimizing risks to establish it as a safe and effective mainstream cancer therapy.
In summary, CAR T-cell immunotherapy utilizes genetically engineered T cells to target cancer antigens in an antigen-specific manner. While still an investigational therapy with various challenges to address, its ability to induce long-lasting responses makes it a promising new option for treating certain hematologic cancers. With ongoing developments to enhance its efficacy and safety profile, CAR T-cell therapy holds potential to greatly impact clinical outcomes for numerous cancer types.
Get more insights on CAR T Cell Therapy
